ISSN: 1874-4710

Journal Home

Journal Guideline

Current Radiopharmaceuticals Q3 Unclaimed

Bentham Science Publishers United Arab Emirates

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Current Radiopharmaceuticals is a journal indexed in SJR in Pharmacology and Radiology, Nuclear Medicine and Imaging with an H index of 35. It has an SJR impact factor of 0,297 and it has a best quartile of Q3. It has an SJR impact factor of 0,297.

Type: Journal

Type of Copyright:

Languages:

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Pharmacology (Q3) Radiology, Nuclear Medicine and Imaging (Q3)

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

0,297

SJR Impact factor

35

H Index

40

Total Docs (Last Year)

115

Total Docs (3 years)

2235

Total Refs

143

Total Cites (3 years)

105

Citable Docs (3 years)

1.32

Cites/Doc (2 years)

55.88

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Journal of Clinical Pharmacy and Therapeutics Q3
Anti-Cancer Agents in Medicinal Chemistry Q3
Psychopharmacology Bulletin Q3
Korean Journal of Physiology and Pharmacology Q3
Anti-Cancer Drugs Q3

Compare this journals

Aims and Scope

Best articles by citations

PET/CT Dose Planning for Volumetric Modulated arc Radiation Therapy (VMAT) -Comparison with Conventional Approach in Advanced Prostate Cancer Patients

Re and Tc Complexes with Pyrazolyl-Containing Chelators: from Coordination Chemistry to Target-Specific Delivery of Radioactivity

Obituary

Biological Evaluation of 99mTc-HYNIC-EDDA/tricine-(Ser)3-D4 Peptide for Tumor Targeting

123I-FP-CIT Brain SPECT Findings in Succinic Semialdehyde Dehydrogenase (SSADH) Deficiency

Editorial (Thematic Issue: Lutetium-177 Labeled Therapeutics: Emerging Importance for Cancer Treatment and Therapy of Chronic Disease)

Towards Small Molecule Labelling with 99mTc

Investigation of the 188Re Eluate Suitability for Medical Purposes by Labeling a Bombesin Analog (BN1.1)

PET/MRI in Neuroendocrine Tumours: Blessings and Curses

Some Implications of Receptor Kinase Signaling Pathway for Development of Multitargeted Kinase Inhibitors

Production of No-Carrier Added Lutetium-177 by Irradiation of Enriched Ytterbium-176

Editorial (Thematic Issue: PET/CT in External Beam Radiation Therapy Dose Planning)

SHOW MORE ARTICLES

CT-MIBI-SPECT Fusion Imaging Combined with Gamma Probe for Minimally Invasive Radioguided Parathyroidectomy (MIRP)

The Missed Tc-99m Radiopharmaceuticals for Cardiac Imaging

Respiratory Motion Management in PET/CT: Applications and Clinical Usefulness

Evaluation of the Radioprotective Effects of Melatonin Against Ionizing Radiation-Induced Muscle Tissue Injury

Accurate assessment of whole-body retention for PRRT with 177Lu using paired measurements with external detectors

Monitoring Kidney Function in Neuroendocrine Tumor Patients Treated with 90Y-DOTATOC: Associations with Risk Factors

[11C]Meta-Hydroxyephedrine PET/CT

Feasibility and Evaluation of Automated Methods for Radiolabeling of Radiopharmaceutical Kits with Gallium-68

Acknowledgements to Reviewers:

Estimation of specific activity of 177Lu by 'saturation assay' principle using DOTA as ligand

[177Lu]-DOTA0-Tyr3-Octreotate: A Potential Targeted Radiotherapeutic for the Treatment of Medulloblastoma

Editorial [ Hot topic:F-18 and On-Site Cyclotrons - are they the Future of Nuclear Medicine? (Guest Editors: Adriano Duatti, Sean L Kitson & Luigi Mansi)]